🛒 How to order this item?
100% Genuine Products, Guaranteed
Safe & Secure Payments, Always
Fast, Secure & Efficient Delivery
Proper Packaging
Show More
Linatab 5mg Tablet should be used with caution in patients with a history of alcoholism. Consult your doctor before taking it.
Linatab 5mg Tablet is generally not recommended for use in pregnant women as it is unknown if it is harmful to the unborn child. Consult your doctor before taking it.
It is not known if Linatab 5mg Tablet passes through breast milk. Consult your doctor before taking it.
Linatab 5mg Tablet does not usually affect your ability to drive.
If u have or had a history or evidence of any kidney-related diseases, please consult the doctor before taking medicine.
If u have or had a history or evidence of any liver-related diseases, please consult the doctor before taking medicine.
The mechanism of action of Linatab 5mg Tablet is to increase the body's production of insulin, which efficiently regulates blood sugar. Additionally, it lessens the quantity of a pancreatic hormone called glucagon (glucagon stimulates the liver to create more sugar), which lowers blood sugar levels.
Linagliptin is used to enhance glycemic control in individuals with type 2 diabetes mellitus.
Linagliptin is a medication used to improve glycemic control in individuals with type 2 diabetes. It belongs to the class of drugs known as DPP-4 inhibitors, which work by inhibiting the enzyme dipeptidyl peptidase-4 (DPP-4). DPP-4 is responsible for breaking down incretin hormones such as GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide).
By inhibiting DPP-4, linagliptin increases the levels of active incretin hormones in the blood. These hormones play a crucial role in regulating glucose homeostasis. They stimulate insulin production and release from pancreatic beta cells in response to elevated blood glucose levels. At the same time, they reduce the production of glucagon, a hormone that increases blood glucose levels, from pancreatic alpha cells.
In summary, linagliptin enhances glycemic control by increasing and prolonging the activity of incretin hormones that are usually inactivated by the DPP-4 enzyme. This leads to increased insulin secretion and decreased glucagon secretion, ultimately helping to regulate blood glucose levels in individuals with type 2 diabetes.
For oral administration in adults with type 2 diabetes mellitus, the typical recommended dose of this medication is 5 mg once daily. It is prescribed to lower blood sugar levels and can be used alone or in combination with other common antidiabetic drugs such as metformin, sulfonylurea, pioglitazone, or insulin.
There is no need for dosage adjustment based on age for elderly individuals. Additionally, no dosage adjustment is required for individuals with hepatic or renal impairment.
It is important to note that the safety and efficacy of this medication have not been established for children, and no specific dose recommendations are available for pediatric use.
For individuals with renal impairment, including those with kidney-related issues, no dose adjustment is necessary.
It is crucial to follow the prescribed dosage and consult with a healthcare professional for personalized advice and guidance regarding the use of this medication.
Linatab 5mg Tablet may interact with various medications and conditions. It is important to be aware of these interactions and inform your doctor about any other medications or medical conditions you have. Here are some potential interactions and precautions to consider:
Linagliptin should not be used in patients with a history of hypersensitivity reactions to the medication, such as urticaria (hives), angioedema (swelling), or bronchial hyperreactivity (excessive sensitivity of the airways). If you have experienced these types of reactions to linagliptin in the past, it is important to avoid using this medication.
Additionally, linagliptin is not indicated for the treatment of type 1 diabetes mellitus, as it is designed for use in individuals with type 2 diabetes. Type 1 diabetes is a condition characterized by the inability of the body to produce insulin, and linagliptin primarily targets insulin regulation in type 2 diabetes.
Furthermore, linagliptin should not be used for the treatment of diabetic ketoacidosis (DKA), a serious complication of diabetes that occurs when there is a severe lack of insulin. DKA requires immediate medical attention and treatment, typically involving insulin therapy and fluid replacement.
Linagliptin is classified as Pregnancy Category B, indicating that there are no adequate and well-controlled studies conducted on pregnant women. Therefore, the use of linagliptin tablets during pregnancy should only be considered if absolutely necessary and the potential benefits outweigh the potential risks to the fetus.
The excretion of linagliptin in human breast milk is unknown. It is essential to consult with a healthcare professional before taking linagliptin while breastfeeding. They can provide personalized advice and weigh the potential risks and benefits for both the mother and the infant.
If you are pregnant or breastfeeding or planning to become pregnant, it is important to discuss your medical condition and treatment options with your healthcare provider. They will consider the available information and provide guidance based on your individual circumstances.
Keep away from light and heat in a dry area. Keep out of children's reach.
Disclaimer:
ePharma sole intention is to ensure that its consumers get proper
information as musch as possible. Although we do not guarantee the
accuracy and the completeness of the information that provided and
here information is for informational purposes only.
The information contained herein should NOT be used as a substitute
for the advice of a qualified physician. This may not cover
everything about particular health conditions,
lab tests, medicines, all possible side effects, drug interactions,
warnings, alerts, etc. Please consult your healthcare professional
and discuss all your queries related to any disease or medicine. We
intend to support, not replace, the doctor-patient relationship.